Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BridgeBio Pharma Inc

Healthcare US BBIO

68.0USD
1.20(1.80%)

Last update at 2026-06-15T20:00:00Z

Day Range

66.0068.02
LowHigh

52 Week Range

31.7784.94
LowHigh

Fundamentals

  • Previous Close 66.80
  • Market Cap14768.47M
  • Volume3072235
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-496.63002M
  • Revenue TTM502.08M
  • Revenue Per Share TTM2.62
  • Gross Profit TTM 481.11M
  • Diluted EPS TTM-3.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -734.98600M -542.19400M -653.25100M -484.65200M -586.45400M
Minority interest 8.01M 7.58M 10.05M 3.47M -23.91500M
Net income -729.30600M -535.76200M -643.20200M -493.96400M -639.29700M
Selling general administrative 531.23M 250.93M 150.59M 143.19M 192.21M
Selling and marketing expenses - 21.50M - - -
Gross profit 473.81M 218.02M 6.86M 74.21M 66.60M
Reconciled depreciation 5.43M 6.08M 6.49M 6.77M 5.84M
Ebit -681.88300M -442.90400M -571.96200M -471.87100M -579.74600M
Ebitda -672.88400M -436.82900M -565.46800M -353.67800M -539.67600M
Depreciation and amortization 9.00M 6.08M 6.49M 118.19M 40.07M
Non operating income net other - - - 107.99M 36.96M
Operating income -569.08700M -592.97300M -607.37000M -471.87100M -579.74600M
Other operating expenses 1071.16M 814.88M 616.67M 546.09M 646.35M
Interest expense 53.10M 99.29M 81.29M 80.44M 46.78M
Tax provision 0.43M 1.15M 0.00000M - -
Interest income 19.85M 17.25M 18.04M 7.54M 1.13M
Net interest income -158.38700M -82.04100M -63.25100M -72.89600M -45.64500M
Extraordinary items - - - - -
Non recurring - - - 43.77M -
Other items - - - - -
Income tax expense 0.56M 1.15M 71.51M 9.31M 52.84M
Total revenue 502.08M 221.90M 9.30M 77.65M 69.72M
Total operating expenses 1042.89M 811.00M 614.23M 546.09M 646.35M
Cost of revenue 28.27M 3.88M 2.45M 3.43M 3.11M
Total other income expense net -165.89900M 50.78M -45.88100M -12.78100M -6.70800M
Discontinued operations - - - - -
Net income from continuing ops -732.93800M -543.34700M -653.25100M -484.65200M -586.45400M
Net income applicable to common shares - - - -481.18300M -562.53900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 936.02M 919.34M 546.38M 623.04M 1012.79M
Intangible assets 28.08M 23.93M 26.32M 28.71M 44.93M
Earning assets - - - - -
Other current assets 44.07M 34.87M 24.30M 21.92M 101.34M
Total liab 3012.61M 2376.95M 1888.91M 1867.96M 1878.37M
Total stockholder equity -2076.58100M -1467.90400M -1354.25700M -1254.61700M -870.41400M
Deferred long term liab - - - - -
Other current liab 214.06M 140.28M 122.97M 94.36M 113.31M
Common stock 0.20M 0.20M 0.18M 0.16M 0.15M
Capital stock 0.20M 0.20M 0.18M 0.16M 0.15M
Retained earnings -3821.19400M -3096.26300M -2560.50100M -1918.14900M -1436.96600M
Other liab - - - 26.64M 22.07M
Good will - - - - -
Other assets 140.75M - - 140.81M 33.03M
Cash 570.12M 681.10M 375.94M 376.69M 393.77M
Cash and equivalents - - - - -
Total current liabilities 287.97M 154.40M 143.84M 117.75M 130.13M
Current deferred revenue 20.27M 14.60M 6.10M 8.16M -
Net debt 2158.61M 1049.48M 1363.90M 1346.88M 1332.40M
Short term debt 17.41M 4.51M 4.13M 3.67M 4.94M
Short long term debt - - - - -
Short long term debt total 2728.72M 1730.58M 1739.84M 1723.56M 1726.17M
Other stockholder equity 1734.37M 1628.15M 1206.03M 663.70M 566.53M
Property plant equipment - - - 14.57M 45.97M
Total current assets 753.68M 720.69M 477.59M 505.20M 839.71M
Long term investments 79.97M 143.75M - 43.65M 49.15M
Net tangible assets - - - -1284.91800M -915.34800M
Short term investments 17.36M 0.00000M 58.95M 95.23M 442.89M
Net receivables 139.44M 4.72M 1.75M 17.08M 19.75M
Long term debt 1852.47M 1721.38M 1726.73M 1707.62M 1703.81M
Inventory 26.75M 0.00000M 16.65M 37.93M -68.89700M
Accounts payable 36.23M 9.62M 10.65M 11.56M 11.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 11.28M 3.41M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M 0.00800M 0.03M -0.32800M -0.13200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.16M 0.15M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1918.14900M -1436.96600M
Treasury stock - - - -275.00000M -275.00000M
Accumulated amortization - - - - -
Non currrent assets other -81.44300M 18.20M 22.62M 20.22M 33.03M
Deferred long term asset charges - - - - -
Non current assets total 41.59M 198.65M 68.79M 117.84M 173.08M
Capital lease obligations 10.00M 9.20M 13.11M 15.95M 22.37M
Long term debt total - - - 1707.62M 1703.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -17.19700M 60.78M 54.03M 453.15M -166.23400M
Change to liabilities - - - 9.82M 22.22M
Total cashflows from investing activities -24.48700M 60.78M 54.03M 453.15M -200.82600M
Net borrowings 116.00M 476.58M 0.00000M -20.48600M 1063.61M
Total cash from financing activities 359.29M 748.46M 451.54M -13.13400M 736.45M
Change to operating activities - - - -2.00300M 12.52M
Net income -724.93100M -543.34700M -643.20200M -484.65200M -586.45400M
Change in cash -111.10400M 288.51M -22.15200M 20.52M 37.69M
Begin period cash flow 683.24M 394.73M 416.88M 396.37M 358.68M
End period cash flow 572.14M 683.24M 394.73M 416.88M 396.37M
Total cash from operating activities -445.91000M -520.72600M -527.72000M -419.49400M -497.93400M
Issuance of capital stock 0.00000M 314.74M 449.81M 4.85M 0.00000M
Depreciation 5.97M 6.08M 6.49M 6.77M 5.84M
Other cashflows from investing activities -6.19300M -7.97500M -0.50300M 115.77M -21.34600M
Dividends paid - - - - -3.82100M
Change to inventory -25.30700M 0.00000M -15.32800M - -
Change to account receivables -134.72200M -2.97100M 15.33M 15.17M -19.74900M
Sale purchase of stock -48.27600M -7.52600M -6.88000M -1.56100M -204.74600M
Other cashflows from financing activities -12.07600M -35.34100M 8.61M 4.06M 1065.31M
Change to netincome - - - 112.72M 111.13M
Capital expenditures 1.10M 0.93M 1.31M 6.32M 48.25M
Change receivables - - - - -
Cash flows other operating - - - -72.71600M -56.46700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 20.52M 37.69M
Change in working capital -51.06400M 32.04M 5.06M 28.08M -4.39600M
Stock based compensation 133.02M 95.80M 115.02M 91.56M 99.50M
Other non cash items 191.09M -111.29600M 103.93M -61.25100M 18.50M
Free cash flow -447.00700M -521.65900M -529.02600M -425.81500M -546.18000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BBIO
BridgeBio Pharma Inc		 1.20 1.80% 68.00 - - 29.41 123.68 32.15 -9.3955
NVO
Novo Nordisk A/S		 0.04 0.09% 43.92 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.40 0.91% 44.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.54 1.24% 450.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.84 0.46% 614.98 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc

3160 Porter Drive, Palo Alto, CA, United States, 94304

Key Executives

Name Title Year Born
Dr. Neil Kumar Ph.D. Co-Founder, Pres, CEO & Director 1979
Dr. Charles J. Homcy M.D. Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director 1948
Dr. Brian C. Stephenson C.F.A., Ph.D. CFO, Sec. & Principal Accounting Officer 1981
Dr. Richard H. Scheller Ph.D. Chairman of R&D and Director 1953
Dr. Frank McCormick Ph.D. Co-Founder & Chairman of Oncology 1950
Dr. Uma Sinha Ph.D. Chief Scientific Officer 1957
Grace Rauh VP of Communications NA
Mr. Eli M. Wallace Ph.D. Chief Scientific Officer of Oncology 1967
Dr. Thomas Trimarchi Ph.D. Chief Product Officer NA
Dr. Eric Michael David J.D., M.D., Ph.D. Chief Exec. Officer of Gene Therapy 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.